<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115086</url>
  </required_header>
  <id_info>
    <org_study_id>031CHO15001</org_study_id>
    <nct_id>NCT03115086</nct_id>
  </id_info>
  <brief_title>The REPLACE Registry for Cholbam® (Cholic Acid)</brief_title>
  <official_title>A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry to Collect Data on Routine Clinical Care in Patients Treated With Cholbam® (Cholic Acid)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Travere Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Travere Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational, non-interventional patient registry study designed to&#xD;
      document product safety and effectiveness outcomes for 10 years in patients treated with&#xD;
      Cholbam, including those who have been using Cholbam for at least 30 days (existing users)&#xD;
      and those who are first-time initiators of Cholbam.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No experimental intervention is involved. Patients in the Registry undergo clinical&#xD;
      assessments and receive care as determined by the patient's treating physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Anticipated">July 2039</completion_date>
  <primary_completion_date type="Anticipated">July 2038</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Number of participants with worsening cholestasis</measure>
    <time_frame>10 Years</time_frame>
    <description>Worsening cholestasis will be identified by measuring direct total bilirubin concentration in blood and will be defined as a 25% increase from previous measurement if the total bilirubin is &gt;1mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with new-onset cholestasis</measure>
    <time_frame>10 Years</time_frame>
    <description>Patients with new-onset cholestasis will be identified by detecting abnormal direct bilirubin concentration &gt;1mg/dL or direct bilirubin greater than 20% of the total bilirubin if total bilirubin is &gt;5mg/dL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with steatorrhea leading to poor growth</measure>
    <time_frame>10 Years</time_frame>
    <description>Steatorrhea leading to poor growth in children, which will be defined as a decrease in growth percentiles from the original percentile at enrollment to the registry study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in serum levels of fat-soluble vitamins</measure>
    <time_frame>10 Years</time_frame>
    <description>Fat-soluble vitamin (A, D, E, K) deficiencies will be identified by comparing results from serum assays (Vitamin A: Retinol, Vitamin D: 250HD2 + 250HD3, Vitamin K: Serum Vitamin K, Vitamin E: Serum Vitamin E) for each vitamin with standard ranges.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropathic signs or symptoms related to fat-soluble vitamin deficiencies</measure>
    <time_frame>10 Years</time_frame>
    <description>Neuropathic signs or symptoms related to fat-soluble vitamin deficiencies (peripheral neuropathy, cerebellar ataxia) will be assessed by the Investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with growth failure</measure>
    <time_frame>10 Years</time_frame>
    <description>Growth failure that the physician judges to be attributable to malabsorption.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>10 Years</time_frame>
    <description>AEs and SAEs leading to death will be recorded. The relatedness of death to Cholbam or disease progression will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse effects on pregnancy, pregnancy outcomes, and infant status</measure>
    <time_frame>10 Years</time_frame>
    <description>Adverse effects on pregnancy, pregnancy outcomes, and infant status will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Adverse Events (AEs) and Serious AEs (SAEs)</measure>
    <time_frame>10 years</time_frame>
    <description>All other AEs and SAEs will be collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Cholbam dosing regimens and reasons for any dose modifications or treatment discontinuations</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in weight</measure>
    <time_frame>10 years</time_frame>
    <description>For patients aged 18 years of or less, these data will be converted into Z-scores based on the WHO growth standards for infants aged 0-2 years and the Centers for Disease Control and Prevention growth standards for children 2-20 years. Growth failure will be defined as a decrease in percentiles from the original percentile at entry point into the registry study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in length/height</measure>
    <time_frame>10 years</time_frame>
    <description>For patients aged 18 years of or less, these data will be converted into Z-scores based on the WHO growth standards for infants aged 0-2 years and the Centers for Disease Control and Prevention growth standards for children 2-20 years. Some patients will be adult or will have achieved final height. Growth failure will be defined as a decrease in percentiles from the original percentile at entry point into the registry study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in head circumference in infants</measure>
    <time_frame>10 years</time_frame>
    <description>For patients aged 18 years of or less, these data will be converted into Z-scores based on the WHO growth standards for infants aged 0-2 years and the Centers for Disease Control and Prevention growth standards for children 2-20 years. Growth failure will be defined as a decrease in percentiles from the original percentile at entry point into the registry study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age-appropriate developmental milestones in infants</measure>
    <time_frame>10 years</time_frame>
    <description>Measured by WHO Motor Development Milestones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in prothrombin time (PT)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in international normalized ratio (INR)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in albumin</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bilirubin</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in direct bilirubin</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in alanine aminotransferase (ALT)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in aspartate aminotransferase (AST)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gamma-glutamyl transferase (GGT)</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in alkaline phosphatase</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of urinary bile acids and levels of bile acid intermediaries and urinary bile alcohol</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All indications for which Cholbam has been prescribed</measure>
    <time_frame>10 years</time_frame>
    <description>Description of all indications for which Cholbam has been prescribed</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Bile Acid Synthesis Disorders</condition>
  <arm_group>
    <arm_group_label>Existing User</arm_group_label>
    <description>Patients who have been using Cholbam for at least 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New User</arm_group_label>
    <description>First-time initiators of Cholbam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholbam</intervention_name>
    <description>Cholbam prescribed according to the approved label.</description>
    <arm_group_label>Existing User</arm_group_label>
    <arm_group_label>New User</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a diagnosis for which Cholbam is indicated are eligible for inclusion in&#xD;
        the Registry.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients, of any age.&#xD;
&#xD;
          2. The patient and/or the patient's parent/legal guardian is willing and able to provide&#xD;
             signed informed consent, and the patient, if less than 18 years of age, is willing to&#xD;
             provide assent as appropriate and in accordance with local regulatory, IRB, and EC&#xD;
             requirements.&#xD;
&#xD;
          3. The patient has a diagnosis for which Cholbam is indicated.&#xD;
&#xD;
          4. The patient is or will be treated with Cholbam at the time of signing the informed&#xD;
             consent form (ICF) (enrollment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients who, by judgement of the Investigator, will not be able to comply with the&#xD;
        requirements of the protocol will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feriandas Greblikas, MD</last_name>
    <role>Study Director</role>
    <affiliation>Senior Medical Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Travere Medical Information</last_name>
    <phone>1-877-659-5518</phone>
    <email>medinfo@travere.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Enns, MB ChB</last_name>
      <phone>650-498-5798</phone>
      <email>genns@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thu Quan</last_name>
      <phone>650-736-8166</phone>
      <email>tquan@stanford.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UC San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Rosenthal, MD</last_name>
      <phone>415-476-7114</phone>
      <email>prosenth@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Camille Langlois</last_name>
      <phone>415-476-1756</phone>
      <email>Camille.Langlois@ucsf.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kidz Pediatric Multispecialty Group</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aymin Delgado, MD</last_name>
      <phone>954-967-9400</phone>
      <email>adelgado@kidzmedical.com</email>
    </contact>
    <contact_backup>
      <last_name>Gerard Minor</last_name>
      <phone>954-579-2072</phone>
      <email>gminor@kidzmedical.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nemours duPont Pediatrics Specialty Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine McGoogan, MD</last_name>
      <phone>904-697-3756</phone>
      <email>katie.mcgoogan@nemours.org</email>
    </contact>
    <contact_backup>
      <last_name>Lynnette Lee</last_name>
      <phone>904-697-2128</phone>
      <email>Lynnette.Lee@nemours.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvin Freeman, MD</last_name>
      <email>afreem6@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Stallworth</last_name>
      <email>Angela.Stallworth@choa.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Center For Digestive Health</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Community Health Clinic</name>
      <address>
        <city>Topeka</city>
        <state>Indiana</state>
        <zip>46571</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zineb Ammous, MD</last_name>
      <phone>260-593-1008</phone>
      <email>zammous@indianachc.org</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Chupp</last_name>
      <phone>260-593-0108</phone>
      <email>schupp@indianachc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Sudel, MD</last_name>
      <phone>612-625-0233</phone>
      <email>bsudel@umn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shannon Swim</last_name>
      <phone>612-709-4438</phone>
      <email>riggs049@umn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Office of Dr. Esperanza Font-Montgomery MD</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esperanza Font-Montgomery, MD</last_name>
      <email>fontmontgomerye@health.missouri.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University at St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janis Stoll, MD</last_name>
      <phone>314-454-6173</phone>
      <email>stoll_J@kids.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stacy Postma</last_name>
      <phone>314-747-5931</phone>
      <email>postmas@wustl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Icahn School Of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Chu, MD</last_name>
      <email>Jaime.Chu@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Marjorie Nisenholtz</last_name>
      <phone>212-659-8049</phone>
      <phone_ext>88049</phone_ext>
      <email>Marjorie.Nisenholtz@mountsinai.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Ovchinsky, MD</last_name>
      <phone>718-741-2332</phone>
      <email>novchins@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Trang Nguyen</last_name>
      <phone>718-741-2557</phone>
      <email>trannguy@montefiore.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital, URMC</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nanda Kerkar, MD</last_name>
      <phone>585-275-2647</phone>
      <email>Nanda_Kerkar@URMC.Rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Fernando Escobedo</last_name>
      <phone>585-273-4879</phone>
      <email>Fernando_Escobedo@URMC.Rochester.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Lichtman, MD</last_name>
      <phone>919-966-2419</phone>
      <email>Lichtman@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nancy Garbarino</last_name>
      <phone>919-843-8734</phone>
      <email>Nancy84@med.unc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James E Heubi, MD</last_name>
      <phone>513-636-4415</phone>
      <email>james.heubi@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Andre Hawkins</last_name>
      <phone>513-636-8549</phone>
      <email>andre.hawkins@cchmc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sirish Palle, MD</last_name>
      <phone>405-271-6306</phone>
      <email>Sirish-Palle@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Tara Waldman, MD</last_name>
      <phone>215-590-1719</phone>
      <email>waldman@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Geraldine Liu</last_name>
      <phone>267-425-2063</phone>
      <email>LiuG@email.chop.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Monroe-Carell Jr. Children's Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynette Gillis, MD</last_name>
      <phone>615-322-7449</phone>
      <email>Lynette.Gillis@vanderbilt.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alexandrea Manis</last_name>
      <phone>615-875-4940</phone>
      <email>alexandrea.manis@vumc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Book, MD</last_name>
      <phone>801-662-2940</phone>
      <email>Linda.Book@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ann Rutherford</last_name>
      <phone>801-585-9495</phone>
      <email>Ann.Rutherford@hsc.utah.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bile Acid Synthesis Disorder</keyword>
  <keyword>Zellweger Spectrum Disorder</keyword>
  <keyword>Peroxisomal Disorder</keyword>
  <keyword>Cholic Acid</keyword>
  <keyword>Cholbam</keyword>
  <keyword>The REPLACE Registry</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

